Skip to content

The Past and Future of Psychedelic Science: An Introduction to This Issue

Lisa Jerome, Brad Burge, Richard Doblin, Merete Bruun Christiansen

Journal of Psychoactive Drugs March 15, 2019 DOI: 10.1080/02791072.2019.1606472 via OpenAlex

Summary

AI-generated from the abstract

Psychedelic plants and fungi have been used in indigenous healing for millennia. Modern research began with Albert Hofmann's synthesis of LSD-25 in 1938, and his accidental self-ingestion in 1943. After scientific and cultural exploration in the 1950s and 1960s, research was nearly halted by government restrictions in the 1970s and 1980s, despite evidence of limited medical risks and therapeutic potential. Today, rigorous studies are abundant, including clinical trials with MDMA-assisted therapy for PTSD, alcoholism, and social anxiety, psilocybin studies for depression and addiction, investigations into psychedelics' ability to catalyze spiritual experiences and inspire creativity, and neuroscientific research on their nervous system effects.

Study at a glance

Characteristics Review Peer reviewed
Topics Addiction Anxiety LSD Psilocybin
Keywords Creativity Psychology Hallucinogen
Citations 87
Key finding After decades of suppression, rigorous psychedelic research is now abundant, encompassing clinical trials for psychiatric conditions, studies of mystical experiences, and neuroscientific investigations.

Abstract

Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and '60s, psychedelic research was slowed to a near halt. Throughout the 1970s and '80s governmental interventions severely hampered global psychedelic research, despite evidence of the limited medical risks and therapeutic potential of psychedelics. After decades of persistent education and advocacy, rigorous research employing psychedelics as tools of discovery and healing are abundant today. Studies are taking place in research institutions and in private practice sites supported by non-profit and for-profit organizations, as well as individual investigators. This research includes clinical trials with MDMA-assisted therapy for the treatment of PTSD, alcoholism, and social anxiety, and psilocybin clinical studies for depression and addiction, as well as the ability of psychedelics to catalyze spiritual or mystical experiences and inspire creativity, and into the neuroscientific understanding the effects of psychedelic substances on our nervous system.

Explore topics

Comments

No comments yet.

Log in to comment